BUSINESS
Cipla: Non-US markets to drive growth in the near term
Reduced contribution of Revlimid is likely to get offset by new products
BUSINESS
Dr Reddy’s: Near-term growth outlook is opaque
The medium-term triggers for the company include a launch pipeline for Semaglutide in non-US markets and the progress of biosimilars.
BUSINESS
Himadri Speciality: Strategically positioned to emerge as a battery chemicals giant
The company benefitted from lower raw material costs, productivity, and higher salience of high-margin products, leading to continued expansion in gross margins.
BUSINESS
Anthem Biosciences IPO: Promising, but pricey play on global CRDMO tailwind
The company offers integrated services across the drug discovery, development, and manufacturing lifecycle for both NCEs and NBEs, including specialised fermentation-based APIs
BUSINESS
Aarti Industries: Return ratios to light up with better sweating of assets
While a large number of end markets are showing an improving outlook, in the near term, pricing pressure is expected to continue.
BUSINESS
Balaji Amines: Is caution warranted after the run-up?
Among the end markets, the pharmaceutical sector has shown stable demand, but the agrochemical segment remains fragile
BUSINESS
Nocil: Valuation factoring in near-term challenges
While the current challenges due to dumping and moderate domestic growth expectations are a dampener, the company is positioning well for the upcoming opportunities
BUSINESS
How to navigate markets amid Fed’s pause and stagflation risks
There are quite a few factors that make the future global economic scenario uncertain for now
BUSINESS
SRF’s profit margins likely to strengthen in FY26
A strong showing has led to an upward revision in its capex guidance for the year. Post its share price run-up, is there still value left?
BUSINESS
Weekly tactical pick: Does this pharma major merit a look despite the regulatory noises?
The fundamentals of the company should be judged based on the specialty pipeline and a strong footing in the domestic market
BUSINESS
HEG: Industry-wide consolidation augurs well for the pricing dynamics
Trump’s escalation of tariffs on steel products is a key near-term watch
BUSINESS
Galaxy Surfactants: A business with a strong defensive profile
The pricing trajectory of fatty alcohol is a key factor to watch
BUSINESS
Divi’s Lab: Capex cycle picks up to meet emerging CDMO demand
The company’s top line is likely to grow in double digits going forward
BUSINESS
Sai Life Sciences: Beneficiary of pricing regulation in the US
The company’s capability enhancement is geared for emerging tailwinds, ranging from the China +1 opportunity to the recent pricing regulation in the US.
BUSINESS
Cipla: Largely unaffected by the Trump’s executive order
The medium-term growth drivers include the global rollout of respiratory and GLP-1 drugs.
BUSINESS
What does Trump’s MFN clause mean for the Indian pharma landscape?
The new regulation appears to be less disruptive for the Indian generics; may impact those having exposure to speciality/patented portfolios
BUSINESS
Trump’s drug pricing regulation: How does it impact Indian pharma?
Pharma players working on speciality/patented portfolios could be impacted more
BUSINESS
Navin Fluorine: Multiple agreements, new capacities strengthen outlook
The company could benefit from the China-plus-one theme in fluorine chemistry
BUSINESS
Resilient US economy buys Fed time amid tariff turbulence
India gains ground as Fed maintains rates and investors seek stability beyond the West
BUSINESS
UK-India FTA: Sectoral shake up – who gains, who loses?
Key Indian export sectors to benefit are, textiles, leather, footwear, marine products, gems & jewellery, auto parts, engineering goods, and organic chemicals.
BUSINESS
Himadri Specialty: Near-term growth triggers missing
Given the weak domestic demand for the auto sector, an unfavourable supply-demand balance is likely to show up in margins
BUSINESS
Ami Organics: Internal accruals fuel growth capex
While client concentration is a key risk in the early years of building a CDMO business, a strong pipeline of products and capex for R&D augur well for the company
BUSINESS
PCBL: Russian advantage now posing as a liability
In the last couple of years, the company benefitted from shortages of Russian supplies of carbon black to the European markets due to the Russia-Ukraine war and related sanctions
BUSINESS
Laurus Labs: CDMO-led growth to enhance return ratios
Drug discovery and development collaboration are the key drivers for the Indian CDMO industry.
